Investor's Business Daily on MSN2mon
Novocure Withdraws Massive Gain On FDA Approval. Why It Could Struggle To Gain Traction.Novocure stock advanced Wednesday morning — but pulled back from more massive gains — after the Food and Drug Administration ...
Cancer-targeting biotech NovoCure (NASDAQ: NVCR) had some highly positive news from the laboratory to deliver earlier this week, and investors couldn't grab hold of the stock fast enough.
From the beginning of 2024 through Dec. 3, shares of Novocure rose 112% higher. They've been soaring because, in addition to positive pancreatic cancer results, its Optune Lua device earned ...
BAAR, Switzerland, January 03, 2025--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced today that management will participate in the 43 rd Annual J.P. Morgan Healthcare Conference on Wednesday ...
Novocure is seeking regulatory approval in the US, EU, Japan and other key markets after the Phase III PANOVA-3 pancreatic cancer study met its endpoints. The PANOVA-3 study (NCT03377491) met its ...
FDA Approves Novocure’s Innovative HFE Transducer Arrays for Use With Optune Gio® for Glioblastoma
ROOT, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced today that the U.S. Food and Drug Administration (FDA) approved its new Head Flexible Electrode (HFE) transducer arrays for ...
H.C. Wainwright analyst Emily Bodnar maintained a Buy rating on NovoCure (NVCR – Research Report) today and set a price target of $30.00. Don't Miss our Black Friday Offers: Unlock your ...
Evercore ISI raised the firm’s price target on Novocure (NVCR) to $46 from $34 and keeps an Outperform rating on the shares. In the firm’s 2025 outlook note for MedTech, Life Science Tools and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback